Background: To know the effectiveness and tolerance of weekly cisplatin added to radiotherapy (RT) in advanced carcinoma of oropharynx and nasopharynx. Results: One hundred and fifty-three patients were randomly allocated to the study, 76 in RT arm and 77 in CRT arm.
introduction
The head and neck cancers constitute 5% of all cancers worldwide and 15% of all cancers in developing countries [1] . Head and neck squamous cell carcinoma (HNSCC) is one of the commonest cancers in India. Of the 600 000 new head and neck cancer cases diagnosed each year, 25% are from India [1, 2] . Treatment of early-stage tumors involves surgery, radiotherapy (RT) or occasionally a combination of two [3] . However, advanced stage requires multimodality treatment, which may be surgery with postoperative RT or chemoradiotherapy (CRT). Currently, the preferred schedule is supposed to be concurrent CRT since disease control is achieved with anatomic and physiologic function preservation. Although HNSCC is sensitive to several anticancer drugs, the unresolved issues are whether to use single agent or combination of two or more drugs and whether to deliver chemotherapy in weekly, daily or 3-weekly schedules [4] .
A number of trials including meta-analyses were available in the literature giving conflicting results whether addition of chemotherapy definitely leads to improvement in survival at the time this trial was designed in 2003. Also, majority of the trials have taken head and neck cancer as one cancer by clubbing all subsites; however, we know that outcome and response of different subsites are not the same. It is known that concomitant treatment is more toxic than single modality. In the meta-analysis reported in 2000, comparison of local treatment with or without chemotherapy yielded an absolute benefit of 4% in overall survival (OS) at 2 and 5 years in favor of chemotherapy; however, there was much heterogeneity between timings of chemotherapy. When analyzing the data for concomitant CRT, survival benefit was 8% at 5 years. The authors concluded by saying that 'heterogeneity of data in concomitant setting makes a conclusion difficult' [3] . An update of this analysis focusing on chemoradiotherapy (with additional 24 trials) reiterated a 4.5% absolute benefit (OS) for all and 6.5% (P value of <0.0001) for patients who received concurrent CRT [5] . Before these reports, the Intergroup 0099 study confirmed that chemotherapy concurrent with RT followed by adjuvant therapy is superior to RT alone for nasopharyngeal cancer [6] . Contrary to this study from the United States, another randomized trial from Hong Kong in advanced nasopharyngeal cancer failed to show significant difference in OS [7] . A meta-analysis limited to nasopharyngeal cancer showed an absolute survival benefit of 6% at 5 years [8] .
Compared with cancers of larynx and hypopharynx, oropharyngeal cancer is more common in developing countries and less amenable to surgery; hence, therapeutic improvement of available modalities is desirable. There are limited randomized trials evaluating CRT versus RT limited to oropharyngeal cancer only. Calais et al. [9] reported that concomitant chemoradiotherapy arm is superior to RT-alone arm in advanced oropharyngeal cancer with regard to OS, disease-free survival (DFS), and locoregional control (3-year OS 51% versus 31%). In another study, only recurrence-free survival was superior in the concomitant arm [10] . Investigators have used daily-or weekly-based chemotherapy schedule [11, 12] . Concurrent chemoradiotherapy using cisplatin 100 mg/m 2 on days 1, 22, and 43 is considered standard for locally advanced HNSCC. Whether weekly dose of 40 mg/m 2 of cisplatin will be equally effective is to be seen in prospective setting.
Unfortunately, from India where HNSCC is a common cancer, there are insufficient data about the feasibility of CRT practice and its superiority over RT alone. Kumar et al. [13] in 2005 reported phase II data on 95 patients, with a median OS of 12 months and a very high mortality rate of 14% during or within 30 days of therapy.
At the time of designing this study, we decided to test the feasibility of CRT in oropharynx and nasopharynx cancer in a prospective randomized manner. Our study objectives were based upon the context of significant head and neck cancer burden in any Indian cancer center, to utilize single-agent chemotherapy on weekly basis with irradiation, which can be easily practiced. The subsites selected are the ones where efficacy of CRT has been established and surgery is usually not preferred.
patients and methods

study design
A prospective phase II randomized single-center study was conducted at the Dr BR Ambedkar Institute Rotary Cancer Hospital of All India Institute of Medical Sciences, New Delhi. Local ethics committee approved the protocol and the study.
patient population
Patients were eligible for study if they had a confirmed diagnosis of squamous cell carcinoma of oropharynx or nasopharynx, stage II-IV (American Joint Committee on Cancer 5th edition, 1997). For stage II cancer to be part of the study, patients were required to have large T2 lesions. Computed tomography (CT) scan or magnetic resonance imaging was done when disease extent could not be assessed clinically. Patients attending head and neck cancer clinic at our center were examined by a team comprising head and neck surgeons and radiation and medical oncologists. Those who were otherwise eligible to be taken up for radical RT were explained about this study. From June 2003 to July 2005, 190 patients were screened and counseled for the study; of which, 153 randomized patients received therapy and were analyzed (Figure 1 ). At the time this study was planned, cetuximab was not in clinical practice for HNSCC and hence, control arm chosen was RT alone. Patients were randomly assigned to one of the treatment arms through computer-generated lots. Stratification as per primary site was not done. Inclusion criteria also included Karnofsky performance status (KPS) > 70 and normal hematological, renal, and liver functions.
treatment
RT arm-radical RT dose of 70 Gy in 35 fractions over 7 weeks (at five fractions per week; standard fractionation) by using cobalt 60 or linear accelerator, as per current practice. All patients were treated with parallelopposed lateral fields and spinal cord was shielded at 44 Gy. Whenever necessary, CT scan-based three-dimensional conformal RT was utilized in order to limit dose to surrounding organs such as eye, brain, and spinal cord. toxicity. Complete blood counts and serum urea and creatinine were done every week. Responses were assessed 4-6 weeks after the completion of RT and at subsequent follow-up in the clinic at periodic intervals of 2-3 months in the first 2 years and of 4-6 months beyond 2 years of therapy.
study end points
This study was carried out with the following aims and objectives. Primary:
1 To know if addition of concurrent chemotherapy increases the responses in these patients as compared with RT alone. 2 To know the toxicity profile in the two treatment groups. 3 To know the 3-year OS analysis in the two treatment groups.
Secondary:
Progression-free survival (PFS).
Tumor responses were evaluated as per clinical examination between 4 and 6 weeks of completion of therapy. Adverse reactions were graded as per National Cancer Institute-Common Toxicity Criteria version2.0 (https:// webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/Common_Toxicity _Criteria_CTC_v2.htm).
statistical methods
Exact test for contingency tables, Kaplan-Meier estimates for survival, and log-rank tests were used to test for difference in response rates, toxic effects, and survival. We expected a 3-year OS of 60% in the CRT arm and 40% in the RT-alone arm. P values <0.05 were taken as significant. Statistical analysis was done using SPSS 10.0 program.
results
Patients' baseline characteristics including demographic profiles, stages, etc. are given in Table 1 . Both groups were well balanced with regard to age, sex, and clinical stage. However, there was significantly more number of nasopharyngeal cancers in the CRT arm. All efficacy analyses were done on an intentto-treat basis. More than 90% of the patients had stage III or IV cancer at the time of presentation. Node-positive disease was seen in 72.4% and 77.9%, respectively, in the RT and the CRT group. treatment compliance Treatment outcome and toxicity are shown in Table 2 . Majority of patients were able to complete the planned treatment. Seventy-one patients (93.3%) in the RT group and 71 (92.2%) in the CRT group completed treatment with or without delay. However, there were more frequent treatment interruptions (22; 28.9%) in the CRT arm compared with that (7; 9.3%) in the RT arm. These were statistically significant (P = 0.003).
toxicity
Patients who had grade IV myelotoxicity or grade III or IV mucosal toxicity with impaired nutritional intake were admitted for nutritional support. Twelve (16%) patients in the RT-alone arm and 31 (40%) patients in the CRT arm required hospitalization for management of mucosal toxicity and parenteral nutrition (P = 0.002). The commonest toxicity seen were mucositis and vomiting. The grade III and IV acute toxicity was documented in 14 (20%) and 30 (40%) patients in the RT versus the CRT arm, respectively (P = 0.015). All these were reversible. No patient discontinued treatment because of therapy and there was no toxic death reported during this study and analysis period.
response All responses were judged clinically and routine imaging was not done. Complete responses (CRs) for the RT arm versus the CRT arm were seen in 51 (67.1%) versus 62 (80.5%) patients, respectively (P = 0.044). Locoregional residual disease was seen in 25 (32.9%) in the RT-alone arm compared with 15 (19.5%) in the CRT arm. Whenever possible, tissue diagnosis was obtained to confirm residual locoregional disease.
During follow-up, 36 and 26 patients in the RT and CRT groups, respectively, progressed at locoregional sites. However, distant metastases were more common in the CRT group (eight compared with three in the RT-alone group). Figure 2 , giving an absolute survival advantage of 20% for the CRT arm. However, statistically significant difference in PFS between the two groups was not observed. Median PFS for RT arm was 22 months compared with 24 months in CRT arm (P = 0.3). OS for the two arms is shown in Figure 2 . PFS for the two arms is shown in Figure 3 .
To know the various prognostic factors for survival, univariate and multivariate analyses using Cox regression method were done (Table 3) . Among the various factors, treatment arm (CRT versus RT) with P value of 0.045, achievement of clinical CR versus no CR with P value of 0.000, and no disease progression versus progression with P value of 0.000 were found significant to improve OS. In multivariate analysis also, all these factors were found significant with P values of 0.049, 0.000, and 0.002 for treatment arm, CR, and no progression, respectively. For PFS also, achievement of CR came out as an independent prognostic factor in multivariate analysis (P = 0.000). [9] reported that concomitant chemoradiotherapy arm is superior to RT-alone arm in advanced oropharyngeal cancer with regard to OS, DFS, and locoregional control (3-year OS 51% versus 31%). However, in this trial, DDP and continuous infusion of 5-FU were used. In another study, even though recurrence-free survival was superior in the concomitant arm, OS was not different [10] . In the French trial (GORTEC 94-01), 226 stage III or IV oropharyngeal cancer patients were randomly assigned to RT alone or RT with 5-FU and carboplatin. Five-year OS (22.4 versus 15.8; P = 0.05) and DFS (26.6 versus 14.6%; P = 0.001) favored chemoradiotherapy arm [14] . Cmelak et al. in a phase II trial with the aim of organ preservation in locally advanced laryngeal and oropharyngeal cancer reported that with paclitaxel and concurrent RT, 2-year survival rate was 83% in the subset of oropharyngeal primary; >90% of patients could complete full-dose RT and at least 5 weeks of paclitaxel. Twoyear organ preservation rate was 81%. In this trial, induction chemotherapy was also used [15] .
Weekly cisplatin is being explored as an alternative to highdose 3-weekly cisplatin in concurrent setting. One phase II study has been reported from India. Kumar et al. [13] reported phase II data consisting of 95 patients with advanced HNSCC involving various subsites. Patients were given CRT using 35 mg/m 2 of cisplatin. Compliance for RT and chemotherapy was, respectively, 66% and 73% only. Grade III/IV mucosal toxicity was seen in 79% of patients. Median OS reported was 12 months with the probability of 3-year survival being 27%. They reported a very high mortality rate of 14% during or within 30 days of therapy. Poor nutrition and dehydration were contributory factors for mortality in at least three of them. Compared with this study, our data reported grade III or IV toxicity in 40% of patients and no therapy-related death reiterating that good supportive care can help in checking morbidity and mortality. Also, >90% of patients were able to complete treatment albeit with interruptions in 28% in the CRT arm.
In the landmark Intergroup 0099 trial, 147 stage III-IV nasopharyngeal cancer patients were randomly assigned to RT alone or RT with concurrent cisplatin, followed by adjuvant cisplatin and 5-FU. RT was delivered by two-dimensional planning technique. In this trial, 63% patients could complete planned chemoradiation and only 55% could complete adjuvant chemotherapy. Five-year OS was 67% versus 37% (P = 0.001) and PFS was 58% versus 29% (P < 0.001), both favoring the CRT arm [6, 16] . Wee et al. [17] reported results from a trial which was similar in design to Intergroup 0099. In this study, 2-year distant metastases were 13% versus 30% (0.0029) in the CRT versus the RT-alone arm. One of the initial trials using weekly DDP in nasopharyngeal cancer was reported by Chan et al. [18] from Hong Kong. In this trial, 5-year OS was 70.3% versus 58.6% (P = 0.049) for the CRT and the RT arm, respectively.
Three-year OS and toxicity reported here are comparable with or better than other published literature [9, 10] . Grade III and IV toxic effects in the CRT arms were >70% in the studies by Calais et al. [9] and Briezel et al. [10] and 50% in the study by Chan et al. [18] . In the present report, we did not use adjuvant chemotherapy for nasopharyngeal cancer. We are not sure if the adjuvant chemotherapy could have improved the outcome further. The difference in PFS between the two groups in this trial was not statistically significant. Median PFS was 22 months for the RT-alone group compared with 24 months for the CRT group (P = 0.3). One possible explanation and flaw in the study may be that since there were more patients with nasopharyngeal primary in the CRT group who as expected developed distant metastases and the benefit of CRT was offset by increased number of distant failures. There were eight patients in the CRT arm who developed distant metastases compared with three in the RT group; six of the distant failures in the CRT arm had nasopharynx as the primary site.
conclusions
This Indian trial confirms that chemoradiotherapy using singleagent weekly DDP is safe and superior to RT in advanced oropharyngeal and nasopharyngeal cancers even in developing countries and can replace 3-weekly high-dose DDP. However, there is requirement of good supportive care and interdepartmental coordination at the treating center. Treatment interruptions and toxic effects are expected and may be of concern, when adequate adherence to chemoradiation schedule is intended. The high compliance rate achieved in this study makes this approach well suited for nonsurgical-site tumors of the head and neck region. 
